Cancer Cover-Up

Aloe Vera and AIDS

Quoting from the December 1994 Issue of
Better Nutrition for Today's Living:

In the early 1990's, Maurice C. Kemp, Ph.D., a visiting scientist at Texas A&M University at College Station, and colleagues at other facilities, began investigating a complex carbohydrate compound purified from the aloe vera plant, which appears to help drugs such as azidothyamidine (AZT) and acyelovir (ACY) block the pathology associated with the human immunodeficiency virus (HIV) and herpes simplex (HSV), according to Gene Charleton, chief science and medical writer at Texas A&M. The research team found that the compound - acemannan - interfered with HIV's ability to reproduce in infected cells.

Of special interest to the researchers was how acemannan affects the immune system's response to a viral infection. They also wanted to know how the substance affects the ability of ACT and ACY to block the spread of HIV and HSV.

The Food and Drug Administration has recently given a Texas laboratory - which isolated acemannan in 1984 - permission to begin human trials on HIV and AIDS patients using their trademarked acemannan compound, reported the Fall 1994 issue of The Journal, a publication of the IASC.

Phase I of the trials will begin in a few months and follow on the heels of a Canadian government -sponsored Phase III study, which used oral acemannan in their human trials, conducted at the Texas Health Science Center in Houston. They also conducted a "safety study" using injectable acemannan, the publication reported.

"As The Journal understands the action of acemannan, it is not a 'cure' for AIDS," the publication said. "Rather, it arrests the syndrome's progression, enabling the patient to live out a more or less normal life span, when used in conjunction with AZT."

The Texas laboratory is not releasing details of its treatment program.

Ian Tizard of Texas A&M University at College Station, who is on temporary assignment at the University of California at San Francisco, reported in the August 21, 1991 issue of Medical Tribune that acemannan, a compound of Aloe vera, "helps AZT (the AIDS drug) block the human immunodeficiency virus from spreading to other cells, and may interfere with HIV replication."

Outrageous: The FDA approved intravenous administration of Aloe (i.e. acemannan) in a very successful study (circa 1993/1994); yet, the FDA takes the public position that intravenous administration of aloe is against the law --- What law?

More outrageous: When two separate Freedom of Information Requests were submitted to the FDA to obtain information regarding the FDA's involvement in human studies of Aloe (i.e. acemannan). The FDA replied:

"The information is proprietary …"
"We have no information …"

WHAT IS THE FDA COVERING-UP?
WHO IS THE FDA COVERING FOR?

The Maryland Attorney General still refuses to allow T-UP, Inc. to provide information to the public about concentrated aloe's many potential benefits:

1. In spite of numerous successful studies, including FDA approved Phase I Safety investigations
2. In spite of the fact that one company has submitted an investigative new drug (IND) application to the FDA for the testing of aloe (i.e. acemannan) in humans; that IND has still not been approved six years after being submitted.